Regencell Bioscience Current Financial Leverage
| RGC Stock | USD 5.10 0.60 10.53% |
Regencell Bioscience holds a debt-to-equity ratio of 0.069. At present, Regencell Bioscience's Debt To Assets are projected to increase slightly based on the last few years of reporting. The current year's Long Term Debt To Capitalization is expected to grow to 1.66, whereas Short and Long Term Debt Total is forecasted to decline to about 396.4 K. Regencell Bioscience's financial risk is the risk to Regencell Bioscience stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Regencell Bioscience's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Regencell Bioscience's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Regencell Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Regencell Bioscience's stakeholders.
For most companies, including Regencell Bioscience, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Regencell Bioscience Holdings the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 4.1212 | Book Value 0.924 | Return On Assets (0.26) | Return On Equity (0.42) |
Regencell |
Regencell Bioscience Financial Leverage Rating
Regencell Bioscience Holdings bond ratings play a critical role in determining how much Regencell Bioscience have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Regencell Bioscience's borrowing costs.| Piotroski F Score | 4 Poor |
| Beneish M Score | -4.56 Unlikely Manipulator |
Regencell Bioscience Debt to Cash Allocation
As Regencell Bioscience Holdings follows its natural business cycle, the capital allocation decisions will not magically go away. Regencell Bioscience's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company has 463.67 K in debt with debt to equity (D/E) ratio of 0.07, which may show that the company is not taking advantage of profits from borrowing. Regencell Bioscience has a current ratio of 13.66, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Regencell Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Regencell Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regencell Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regencell to invest in growth at high rates of return. When we think about Regencell Bioscience's use of debt, we should always consider it together with cash and equity.Regencell Bioscience Total Assets Over Time
Regencell Bioscience Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Regencell Bioscience's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Regencell Bioscience, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a a Regencell Bioscience debt ratio should be compared their industry average or other competing firms.Regencell Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Regencell Bioscience Use of Financial Leverage
Regencell Bioscience financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Regencell Bioscience's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Regencell Bioscience assets, the company is considered highly leveraged. Understanding the composition and structure of overall Regencell Bioscience debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Regencell Bioscience's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Regencell Bioscience's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 417.3 K | 396.4 K | |
| Net Debt | -991 K | -941.5 K | |
| Short Term Debt | 394.4 K | 374.7 K | |
| Short and Long Term Debt | 4.2 M | 3.2 M | |
| Net Debt To EBITDA | 4.56 | 2.62 | |
| Debt To Equity | (2.76) | (2.90) | |
| Interest Debt Per Share | 15.13 | 15.89 | |
| Debt To Assets | 0.83 | 1.36 | |
| Long Term Debt To Capitalization | 1.58 | 1.66 | |
| Total Debt To Capitalization | 1.57 | 1.65 | |
| Debt Equity Ratio | (2.76) | (2.90) | |
| Debt Ratio | 0.83 | 1.36 | |
| Cash Flow To Debt Ratio | 0.17 | 0.16 |
Currently Active Assets on Macroaxis
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out the analysis of Regencell Bioscience Fundamentals Over Time. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.